How should I use this medicine?

The dosage of ALKERAN (melphalan) varies based on the patient's condition, requiring careful adjustment based on blood counts and clinical response.

Dosage and Administration Guidelines for ALKERAN (Melphalan)

The recommended dosage of ALKERAN (melphalan) for multiple myeloma is typically 0.2 to 0.25 mg/kg orally, while for non-resectable epithelial carcinoma of the ovary, dosing should be individualized. Dosage adjustments are based on patient blood counts, particularly platelet count, white blood cell count, and hemoglobin levels. Blood counts should be monitored regularly to assess bone marrow suppression and to avoid further toxicity. If significant bone marrow suppression, such as thrombocytopenia or leukopenia, is detected, treatment should be withheld until blood counts recover. Renal function may also influence dosing decisions.